Accure Therapeutics is a R&D pharma company dedicated to developing innovative medicines to treat patients suffering from Central nervous system (CNS) diseases, a major medical challenge.
Total raised: $9.97M
Investors 2
| Date | Name | Website |
| - | Alta Life ... | altals.com... |
| 05.11.2025 | Asabys Par... | asabys.com... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.04.2025 | - | $1.6M | - |
| 27.05.2020 | Series A | $8.37M | - |
Mentions in press and media 14
| Date | Title | Description |
| 12.04.2025 | The Dawn of a New Era in Neurology: Innovations Reshaping Diagnosis and Treatment | The world of neurology is undergoing a seismic shift. New technologies are like fresh paint on an old canvas, revealing vibrant possibilities for diagnosis and treatment. From advanced imaging techniques to groundbreaking gene therapies, th... |
| 07.04.2025 | Accure Therapeutics secures $1.6M from Michael J. Fox Foundation and Luxembourg national research Fund | Barcelona neuroscience R&D company Accure Therapeutics has received two grants totalling €1.46 million for two separate development programs on its drug candidate ACT-02. ACT-02 is a novel asset with disease-modifying potential, inhibit... |
| 16.05.2024 | Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy | Read the full press release here: https://accure.health/accure-therapeutics-awarded-e1-million-from-spanish-government-to-evaluate-act-03-for-post-traumatic-epilepsy/ |
| 06.03.2024 | Which are Barcelona’s Most Influential Biotechnology Startups in 2023? | Barcelona, the cosmopolitan capital of Spain’s Catalonia region, is famed not only for its art and architecture but also for its bustling biotechnology startup scene. Catalonian biotech startups have been turning heads globally thanks to th... |
| 24.01.2024 | Who are Catalonia’s Most Influential Game-Changers in Biotech, 2023? | The biotechnology scene in Catalonia, Spain, is thriving, with many innovative start-ups to its credit. Each of these companies is working towards the monumental task of pushing the boundaries of science to shape the future of healthcare, l... |
| 03.03.2022 | Oculis in-licenses neuroprotective drug candidate for glaucoma | |
| 02.03.2022 | Oculis Strengthens Leading Ophthalmology Pipeline by InLicensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics | Lausanne, Switzerland, and Barcelona, Spain, March 2, 2022 – Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics,... |
| 02.03.2021 | Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01 | https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/ |
| 12.02.2021 | Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy | https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/ |
| 10.02.2021 | Accure Therapeutics – Webinars on Neuroprotection for Brain Diseases Program | https://accure.health/webinars-on-neuroprotection-for-brain-diseases-program/ |
Show more